Table 1. Baseline characteristics of the study population.
| Variable | BMS (n = 644) | DES (n = 322) | |
| n (%) | n (%) | ||
| Sex | 1.0a | ||
| Female | 168 (26.1%) | 84 (26.1%) | |
| Male | 476 (73.9%) | 238 (73.9%) | |
| Age | 1.0a | ||
| 30-64 | 294 (45.7%) | 147 (45.7%) | |
| ≥ 65 | 350 (54.3%) | 175 (54.3%) | |
| (Mean ± SD) | 65.9 ± 12.3 | 65.8 ± 11.9 | 0.92b |
| Premium-based monthly salary ($NT) | < .0001a | ||
| ≤ 19,200 | 162 (25.1%) | 60 (18.6%) | |
| 19,201~21,900 | 225 (35.0%) | 80 (24.8%) | |
| ≥ 21,901 | 121 (18.8%) | 97 (30.1%) | |
| Levels of hospital care | 0.04a | ||
| Medical center | 335 (52.0%) | 190 (59.0%) | |
| Non-medical center | 309 (48.0%) | 132 (41.0%) | |
| Disease severity | |||
| Stent number | 1.0a | ||
| 1 | 492 (76.4%) | 246 (76.4%) | |
| 2 | 128 (19.9%) | 64 (19.9%) | |
| 3 | 24 (3.7%) | 12 (3.7%) | |
| CCI (points) | 1.0a | ||
| 0-1 | 134 (20.8%) | 67 (20.8%) | |
| 2 | 94 (14.6%) | 47 (14.6%) | |
| ≥ 3 | 416 (64.6%) | 208 (64.6%) | |
| Drug therapy | |||
| DAPT | 590 (91.61%) | 303 (94.10%) | 0.2a |
| Statins | 315 (48.91%) | 183 (56.83%) | 0.02a |
a Cochran-Mantel-Haenszel Chi-Square test. b Cox Proportional Hazard Regression Model, based on different stent type.
BMS, bare metal stent; CCI, Charlson comorbidity index; DAPT, dual antiplatelet therapy; DES, drug-eluting stent.